Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Second Quarter 2016 Financial Results
ANN ARBOR, Mich., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol …